Today’s Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics

U.S. equities saw losses on Wednesday, breaking a winning streak of four consecutive days, as trade tensions grew following the White House’s announcement of further tariffs on Chinese goods. The Dow Jones Industrial Average declined 0.88 percent to close at 24,700.45, while the S&P 500 Index dropped 0.71 percent to close at 2,774.02. The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61.

“This is different from the other trade announcements, because the size is significantly larger, and because China is unable to directly reciprocate at $200 billion because they don’t import that much. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.

RDI Initiates Coverage on:

Galmed Pharmaceuticals Ltd.

Akcea Therapeutics, Inc.

Galmed Pharmaceuticals’ stock moved 4.09% lower Wednesday, to close the day at $10.55. The stock recorded a trading volume of 210,784 shares, which was below its three months average volume of 540,028 shares. In the last year, Galmed Pharmaceuticals’ shares have traded in a range of 3.61 – 27.06. The share price has gained 192.24% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $10.77 is above its 200-day moving average of $8.24. Shares of Galmed Pharmaceuticals have gained roughly 50.71 percent in the past month and are up 15.3 percent year-to-date.

Access RDI’s Galmed Pharmaceuticals Ltd. Research Report at:

On Wednesday, shares of Akcea Therapeutics recorded a trading volume of 225,708 shares, which was below the three months average volume of 289,988 shares. The stock ended the day 4.93% higher at $25.33. The share price has fallen 25.48% from its 52 week high with a 52 week trading range of 1.05 – 33.99. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $24.14 is above its 200-day moving average of $22.67. Shares of Akcea Therapeutics have gained roughly 14.98 percent in the past month and are up 45.91 percent year-to-date.

Access RDI’s Akcea Therapeutics, Inc. Research Report at:

Our Actionable Research on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) and Akcea Therapeutics, Inc. (NASDAQ:AKCA) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:



[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.